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Abstract. To develop a scalable and efficient process suitable for the continuous
manufacturing of poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing ovalbumin
as the model protein. PLGA nanoparticles were prepared using a double emulsification
spray-drying method. Emulsions were prepared using a focused ultrasound transducer
equipped with a flow cell. Either poly(vinyl alcohol) (PVA) or poloxamer 407 (P-407) was
used as a stabilizer. Aliquots of the emulsions were blended with different matrix excipients
and spray dried, and the yield and size of the resuspended nanoparticles was determined and
compared against solvent displacement. Nanoparticle sizes of spray-dried PLGA/PVA
emulsions were independent of the matrix excipient and comparable with sizes from the
solvent displacement method. The yield of the resuspended nanoparticles was highest for
emulsions containing trehalose and leucine (79%). Spray drying of PLGA/P-407 emulsions
led to agglomerated nanoparticles independent of the matrix excipient. PLGA/P-407
nanoparticles pre-formed by solvent displacement could be spray dried with limited
agglomeration when PVA was added as an additional stabilizer. A comparably high and
economically interesting nanoparticle yield could be achieved with a process suitable for
continuous manufacturing. Further studies are needed to understand the robustness of a
continuous process at commercial scale.
KEY WORDS: continuous manufacturing; PLGA nanoparticles; focused ultrasound; spray drying;
protein delivery.
INTRODUCTION
Amajor challenge in the translation and commercialization
of nanomaterials in medicine is the development of adequate
pharmaceutical production processes that work equally well at
large scale as at lab scale as (1,2). While several marketed
pharmaceutical products employ nanotechnology, very little is
publicly known about production processes and the translation
from research to commercial scale (3). Continuous processes are
often investigated (2,4,5), as they are considered easy to scale
and more efficient, allow for simple process monitoring, and
typically lead to less batch-to-batch variation. Although
continuous nanoparticle precipitation methods—sometimes
called flash nanoprecipitation—exist (5–7), in general, they are
not suitable to produce nanoparticles of hydrophobic polymers
and hydrophilic cargos. Such systems are often produced using
the double emulsion method (8): the hydrophilic drug is
dissolved in water and emulsified into a non- or partially
miscible solvent containing the polymer. This two-phase system
is further emulsified into an outer aqueous phase containing a
stabilizer. The solvent is subsequently removed and the polymer
precipitates to form nanoparticles around the hydrophilic drug.
The critical steps of emulsification and solvent removal are
typically done with batch processing (9).We previously reported
the use of a focused ultrasound transducer coupled with a flow-
through cell for a contact-free and scalable emulsification
capable of continuous processing (9). The logical next step
would be to also adapt the solvent evaporation to a continuous
process, for example, by spray drying.
Spray drying is a continuous, fast, and efficient process
for solvent removal. It may be used to transform preformed
nanoparticle suspensions to dry powders commonly known as
“Trojan particles,” nanoembedded microparticles, or
nanoparticles-in-microparticles (10,11). The direct precipita-
tion and drying of nanoparticles has been described as the
emulsion spray drying approach, using single water/oil (W/O)
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emulsions (12–15). The size of the precipitated nanoparticles
is controlled by the atomization of the feed rather than by the
droplet size of the dispersed phase of the emulsion.
However, the generation of submicron droplets and
the collection of submicron particles with sufficient yield
are very challenging with conventional equipment, and the
throughput of available specialized equipment is severely
limited compared with conventional nozzles, cyclones, and
filter bags (16).
Spray dying of water/oil/water (W/O/W) double emul-
sions allows for the in situ generation of polymeric nanopar-
ticles with hydrophilic cargo while simultaneously embedding
them in a stabilizing powder matrix. The concept has been
described for batch mode emulsification and conventional
spray drying equipment (17,18), but little is known about the
factors influencing nanoparticle size and yield. The aim of this
study was to investigate whether poly(lactic-co-glycolic acid)
(PLGA) nanoparticles can be produced with acceptable yield
and particle size distribution by the double emulsion method
using scalable methods fit for continuous manufacturing.
Different emulsion stabilizers and matrix components were
investigated for their influence on nanoparticle size and yield.
MATERIALS AND METHODS
Materials
Poly(lactic-co-glycolic acid) (PLGA, Resomer® RG 503
H) was purchased from Evonik Industries (Essen, Germany).
Poloxamer 407 (P-407), Kollidon® 30 (K30), and Kollidon®
VA64 (VA64) were kindly provided by BASF (Ludwigshafen,
Germany). Poly(vinyl alcohol) (PVA; Mowiol® 4–88) was
obtained from Kuraray Europe GmbH (Hattersheim am
Main, Germany). Ovalbumin grade V, as well as all other
chemicals, was obtained from Merck KGaA (Darmstadt,
Germany). Water was purified with a Milli-Q® system
(Merck KGaA; Darmstadt, Germany).
Emulsion Preparation
All solutions were freshly prepared and filtered through
0.2-μm membrane filters (polytetrafluoroethylene for organic
solutions or polyethersulfone for aqueous solutions). Double
emulsions were prepared using focused ultrasound according
to a previously described method (9). In brief, PLGA was
dissolved to 12 mg/mL in 70 mL ethyl acetate and added to
14 mL of an aqueous solution of 6 mg/mL ovalbumin. The
mixture was circulated through the flow cell of a commercial
focused ultrasound transducer (Covaris S2x, Covaris Inc.;
Woburn, MA, USA) using a peristaltic pump at 50 mL/min.
The mixture was homogenized for 5 min at intensity 10, duty
factor 50%, 300 cycles per burst. An aqueous solution,
140 mL of 20 mg/mL PVA or P‐407, was added, and the
mixture was again emulsified by focused ultrasound for
45 min (same settings). An aliquot of this emulsion was
precipitated by solvent displacement (10‐fold dilution with
purified water). The particle size distribution of the obtained
nanoparticle suspension was measured by dynamic light
scattering as described below. The results served as a control
for in‐use emulsion stability and as a target for nanoparticles
precipitated by spray drying.
Spray Drying
Aliquots of the double emulsion, consisting of dry mass
ratios of 1 part PLGA and 3.3 parts PVA or P-407, were
either directly spray dried or spiked with 9 parts matrix
excipient. The aliquots were fed at 2 mL/min into a ProCepT
4M8-TriX lab scale spray dryer equipped with a straight and a
conical drying column and a small cyclone (ProCepT nv;
Zelzate, Belgium); atomized with a 1.0 mm bi-fluid nozzle and
10 L/min nitrogen; and dried at 80°C inlet drying air
temperature, 0.4 m3/min drying air flow, 40–42°C cyclone
outlet temperature, and a pressure drop of 60–65 mbar over
the cyclone. Ambient conditions were between 20 and 23°C
and 40–60% rh.
Particle Size and Yield Determination
Spray-dried powders were reconstituted with purified
water at approximately 0.5 mg/mL PLGA by shaking for 30–
60 min and passed through a 1.0 μm glass microfiber syringe
filter to remove agglomerated PLGAparticles and incompletely
dissolved matrix excipients. The filtered particle suspensions
were analyzed by dynamic light scattering (Zetasizer Nano ZS,
Malvern Instruments; Worcestershire, UK; λ = 633 nm, 25.0 ±
0.1°C, backscatter mode, cumulants fit).
Filtered and unfiltered suspensions were centrifuged for
5 min at 21,000xg to collect the PLGA particles. The pellet
was washed twice with water, dried in a rotary vacuum
concentrator (RVC 2–33 IR, Martin Christ; Osterode, Ger-
many), and subsequently weighed. The nanoparticle yield was
calculated by dividing the mass of the pellet from the filtered
suspension by the mass of the pellet from the corresponding
unfiltered suspension.
RESULTS AND DISCUSSION
Double emulsions containing PLGA and either PVA or
P-407 as the nanoparticle stabilizer were spray dried and
analyzed for changes in particle size distribution and the
resulting nanoparticle yield. The emulsions were either
sprayed “as is” or after the addition of matrix excipients:
trehalose and mannitol as desiccoprotectants, leucine to
increase the dispersibility of the spray-dried powders (19));
VA64 and K30 due to their ability to sterically stabilize drug
nanoparticles (20); or the further addition of the nanoparticle
stabilizers PVA and P-407 also as matrix excipients. Nano-
particle precipitation from PLGA/PVA or PLGA/P-407
double emulsions by solvent displacement without any
additives or spray drying served as the control.
Spray drying of double emulsions containing PLGA/
PVA yielded nanoparticles of similar size as precipitation by
direct solvent displacement (Fig. 1). The addition of different
matrix excipients to the emulsions before drying did not
influence the resulting nanoparticle size. Only P-407 seemed
to decrease the resulting nanoparticle size. P-407 is a surface-
active block copolymer suitable for the stabilization of PLGA
double emulsions and suspensions alone, resulting in particles
of a smaller hydrodynamic diameter when using the same
manufacturing method and parameters (9). A possible
explanation is that P-407 may replace PVA, to a certain
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extent, at the liquid/liquid interface before drying or at the
particle/liquid interface after drying and reconstitution.
In contrast to the mean particle size, the nanoparticle mass
recovery from spray-dried powders is influenced by the choice
of matrix (Fig. 2). Spray drying of the emulsion with no further
addition of excipients resulted in a nanoparticle yield of 40%.
Adding K30 to the emulsion is not beneficial for the nanopar-
ticle yield. Adding mannitol/leucine or VA64 moderately
increases the yield to 50–60%. The best result of 79% was
obtained when trehalose/leucine were added to the emulsion. A
nanoparticle yield of 79% is considerably higher than previously
reported for the continuous production of PLGA nanoparticles
using focused ultrasound followed by solvent displacement (9).
The reported yield may already be economically acceptable
when reproduced on a commercial scale.
After the proposed process, excess stabilizer and free
drug would remain in the spray-dried powder. The spray-
dried powder could be directly used for further downstream
processing (e.g., tableting) into a final dosage form for
applications where free drug and stabilizer are not an issue.
Alternatively, the dry powder intermediate may be purified
before further processing. Centrifuge purification works well
for PVA and is well established at lab scale, but the scalability
is limited and particles may deform or agglomerate under
stress (9). Continuous purification methods, such as cross-flow
Fig. 1. Resulting nanoparticle sizes after spray drying of PLGA/PVA
double emulsions with and without the addition of different matrix
excipients. Spray-dried powders were reconstituted in purified water,
then aggregates were removed by filtration, and particle size distribu-
tion was measured by dynamic light scattering. Nanoparticles precip-
itated by solvent displacement without spray drying served as the
control. Measurements were done in triplicate, RSD < 0.5%
Fig. 2. Resulting nanoparticle yield after spray drying of PLGA/PVA
double emulsions with and without the addition of different matrix
excipients. Nanoparticles were isolated from the matrix after
reconstitution of the complete batch in purified water, then aggre-
gates were removed by filtration, and the mass was determined after
drying
Fig. 3. Resulting nanoparticle sizes after spray drying of PLGA/P-407
double emulsions with and without the addition of different matrix
excipients. Spray-dried powders were reconstituted in purified water,
then aggregates were removed by filtration, and particle size
distribution was measured by dynamic light scattering. Nanoparticles
precipitated by solvent displacement without spray drying served as
the control. Measurements were done in triplicate, RSD < 0.5%
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filtration, are preferred at larger scale, but are challenging for
formulations containing PVA: Residual amounts of PVAwere
found to be several times higher after filtration than after
centrifugation (21,22). P-407 has been previously shown to
work well with the double emulsion solvent displacement
method and is easily removed by crossflow filtration (9).
Therefore, we evaluated the potential of using P-407 with the
double emulsion spray drying method.
Particles of PLGA/P-407 precipitated from the emulsion by
solvent displacement instead of spray drying had a very narrow
size distribution (indicated by a polydispersity index [PDI] of
0.10) and served as the control. Spray drying of emulsions
stabilized with P-407 yielded agglomerated particles (Fig. 3):
Spray drying without further additives resulted in a PDI of 0.57.
The addition of VA64 and K30 did not improve the particle size
distribution (PDI: 0.54–0.56). Using trehalose and leucine or
mannitol and leucine as thematrix excipients resulted in a lower
but still unsatisfactory PDI of 0.38–0.43.
As PLGA/PVA emulsions could be successfully spray
dried when spiked with P-407, it was tested whether the
addition of PVA and trehalose to a PLGA/P-407 emulsion
could positively influence nanoparticle stability. The resulting
PDI of 0.35 was only slightly better than when using trehalose
and leucine. This indicates that the presence of PVA is
already needed during the emulsion step to exert its
stabilizing effect during spray drying. An acceptable PDI of
0.23 could only be achieved when spray drying a suspension
previously precipitated by solvent displacement after the
addition of PVA and trehalose. However, the nanoparticle
yield was unacceptable for all tested formulations of PLGA/
P-407 particles (Fig. 4) and was considerably lower than
previously reported for focused ultrasound followed by
solvent displacement (9). The superiority of PVA may be
attributed to the formation of a thicker and denser surface
layer (indicated by the larger resulting hydrodynamic particle
sizes) and stronger surface binding and retention (23,24),
whereas P-407 adsorbs weaker with i ts middle
poly(oxypropylene) block (25).
CONCLUSION
An economically interesting nanoparticle yield can be
achieved using continuous manufacturing and drying methods.
PVA stabilizes emulsion droplets and PLGA nanoparticles
during spray drying to achieve a high nanoparticle yield and
good particle size distribution, especially in the presence of
trehalose and leucine. P-407 is not an effective stabilizer for the
double emulsion spray drying method, despite being effective
for solvent displacement. Further development work is needed
to link the individual processes in a continuous line and to
investigate process robustness, scalability, and protein loading
efficiency. Further optimization of the emulsion step or use of
different emerging emulsion techniques, such as microfluidics,
would allow for completely continuous manufacturing of
polymeric nanoparticles with an acceptable yield for
commercial-scale manufacturing.
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